CenTrial Logo

TAK-003 Dengue Vaccine Safe and Well-Tolerated in Children and Adolescents


Clinical trial finds TAK-003 vaccine  for dengue fever safe and effective

Dengue is a viral illness caused by the dengue virus, which is transmitted to humans through the bite of infected Aedes mosquitoes, primarily Aedes aegypti. Dengue is a significant public health concern, particularly in tropical and subtropical regions. The symptoms of dengue can range from mild to severe and may include high fever, severe headache, joint and muscle pain, rash, and mild bleeding manifestations such as nose or gum bleeding. In some cases, dengue can progress to a more severe form called dengue hemorrhagic fever (DHF), which can be life-threatening.

There is no specific antiviral treatment for dengue. Management typically involves supportive care such as fluid replacement to maintain hydration, management of symptoms, and close monitoring for signs of severe dengue. Dengue prevention relies mainly on eliminating mosquito breeding sites, using insecticide-treated bed nets, and applying insecticides to control mosquito populations.

Clinical Trial

A clinical trial for a tetravalent dengue vaccine called TAK-003 has shown promising results in children and adolescents living where dengue is endemic. This study analyzed safety data from two phase 2 and three phase 3 clinical trials of TAK-003, involving 14,627 vaccine recipients and 7,167 placebo recipients.

Adverse Events

The most common adverse events reported were injection site pain and headache. These events were mostly mild and resolved within 1-3 days. Unsolicited adverse events and events leading to discontinuation occurred with similar frequency in both the vaccine and placebo groups. Serious adverse events were fewer in TAK-003 recipients than in the placebo. Only four vaccine-related SAEs in the placebo group involved hypersensitivity, dengue fever, and dengue hemorrhagic fever. No deaths were considered vaccine-related. Subgroup analyses showed no differences in safety based on baseline dengue serostatus or gender. However, there were higher rates of local adverse reactions at the injection site in adolescents and adults compared to children.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me


TAK-003 was well tolerated in recipients aged 4-60, regardless of age, gender, or baseline dengue serostatus. No significant safety risks were identified in this integrated data analysis from multiple clinical trials. These findings suggest that TAK-003 has an acceptable safety profile and may be a promising option for dengue vaccination in populations living in dengue-endemic areas, including individuals with or without previous dengue exposure. Further research and regulatory approval are needed to establish the effectiveness and safety of TAK-003 as a dengue vaccine for broader use.

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Without participants there can be no clinical trials.
Without clinical trials there will be no new treatments.
Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.